This is a clinical data update with no near-term revenue catalyst. Monitor for potential biopharma partnership announcements or reimbursement developments following the ASCO presentations. The 97% detection rate and ultrasensitive range data are positive for the test's clinical positioning but do not change the near-term financial outlook.
Price Chart
Executive Summary
Myriad Genetics announced it will present data at ASCO 2026 showing its Precise MRD test achieved 97% baseline detection across multiple cancer types in the MONSTAR-SCREEN-3 study, with 16% of samples detected at ultrasensitive levels. The data supports the clinical utility of the test for recurrence monitoring, but this is a scientific conference presentation with no immediate revenue or regulatory catalyst.
Key Facts
- Precise MRD test achieved 97% baseline ctDNA detection in MONSTAR-SCREEN-3 pan-cancer analysis
- 16% of samples detected in the ultrasensitive range
- ctDNA-positive patients at 1-month post-surgery had significantly worse disease-free survival
- Data presented across six posters at ASCO 2026 covering gastric, ovarian, head/neck, sarcoma, and pan-cancer indications
- No financial terms, revenue guidance, or regulatory milestones disclosed in the press release
Financial Impact
No financial figures disclosed; the press release is a scientific data update with no immediate revenue or cost impact
Risk Factors
- No revenue or regulatory milestones announced; commercialization timeline for Precise MRD remains uncertain
- Competitive MRD tests from Guardant Health, Natera, and others may limit market share
- Company has a small market cap ($364M) and negative historical stock performance following prior reports
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3302066 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 16, 2026 16d ago | 8-K | $3.86 $4.01 | ▲ +3.89% | ▲ +1.32% | $4.54 (+17.62%) |
Sep 16, 2026 16d ago | Press Release | $3.86 $4.01 | ▲ +3.89% | ▲ +1.32% | $4.54 (+17.62%) |
Aug 4, 2026 8w ago | Press Release | $3.17 $3.22 | ▼ −1.58% | ▼ −1.68% | $4.54 (−43.22%) |
Jul 30, 2026 9w ago | Press Release | $2.86 $3.26 | ▼ −13.99% | ▼ −10.47% | $4.54 (−58.74%) |
May 27, 2026 18w ago | Press Release | $3.93 $4.31 | ▲ +9.67% | ▲ +8.46% | $4.54 (+15.52%) |
Mar 17, 2026 28w ago | Press Release | $4.64 $4.68 | ▲ +0.86% | ▲ +1.58% | $4.54 (−2.16%) |
Feb 28, 2026 30w ago | Institutional Cluster | $5.01 $4.81 | ▼ −3.99% | ▼ −2.78% | $4.54 (−9.38%) |
Feb 24, 2026 31w ago | S-3 | $4.78 $5.28 | ▲ +10.46% | ▲ +11.56% | $4.54 (−5.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access